ArticleBMC infectious diseases2017
An evaluation of a recombinant multiepitope based antigen for detection of Toxoplasma gondii specific antibodies.
Article in BMC infectious diseases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- A comprehensive multi-epitope recombinant protein strategy for accurate serological detection of Toxoplasma gondii infection.Medical microbiology and immunology · 2025Article
- Recombinant multiepitope proteins expressed in Escherichia coli cells and their potential for immunodiagnosis.Microbial cell factories · 2024Review
- Congenital Toxoplasmosis Diagnosis: Current Approaches and New Insights.Acta parasitologica · 2023Review
- Assessment of Geographical Distribution of Emerging ZoonoticTropical medicine and infectious disease · 2022Article
- Designing mRNA- and Peptide-Based Vaccine Construct against Emerging Multidrug-ResistantMedicina (Kaunas, Lithuania) · 2022Article
- A Promising Tool in Serological Diagnosis: Current Research Progress of Antigenic Epitopes in Infectious Diseases.Pathogens (Basel, Switzerland) · 2022Review
- Immunoinformatics Design and Assessment of a Multiepitope Antigen (OvMCBL02) for Onchocerciasis Diagnosis and Monitoring.Diagnostics (Basel, Switzerland) · 2022Article
- Descriptive Comparison of ELISAs for the Detection ofPathogens (Basel, Switzerland) · 2021Review
- In-silico design of a multi-epitope for developing sero-diagnosis detection of SARS-CoV-2 using spike glycoprotein and nucleocapsid antigens.Network modeling and analysis in health informatics and bioinformatics · 2021Article
- Molecular Detection and Genetic Diversity ofPathogens (Basel, Switzerland) · 2020Article
- A Review on the Prevalence ofInternational journal of environmental research and public health · 2020Review
- Validation of dried blood spots in monitoring toxoplasmosis.Pathogens and global health · 2020Article
- In Silico Design and Validation of OvMANE1, a Chimeric Antigen for Human Onchocerciasis Diagnosis.Pathogens (Basel, Switzerland) · 2020Article
- Serological and molecular rapid diagnostic tests for Toxoplasma infection in humans and animals.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2020Review
- Review on the Current Trends of Toxoplasmosis Serodiagnosis in Humans.Frontiers in cellular and infection microbiology · 2020Review
- Serological diagnosis of Toxoplasma gondii: analysis of false-positive IgG results and implications.Parasite (Paris, France) · 2020Article
- Epitope-based vaccine as a universal vaccination strategy againstJournal of advanced veterinary and animal research · 2019Review
- Usefulness of paired samples for the Serodiagnosis of toxoplasmosis infection in a tertiary teaching Hospital in Malaysia.BMC infectious diseases · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundThe inefficiency of the current tachyzoite antigen-based serological assays for the serodiagnosis of Toxoplasma gondii infection mandates the need for acquirement of reliable and standard diagnostic reagents. Recently, epitope-based antigens have emerged as an alternative diagnostic marker for the achievement of highly sensitive and specific capture antigens. In this study, the diagnostic utility of a recombinant multiepitope antigen (USM.TOXO1) for the serodiagnosis of human toxoplasmosis was evaluated.
methodsAn indirect enzyme-linked immunosorbent assay (ELISA) was developed to evaluate the usefulness of USM.TOXO1 antigen for the detection of IgG antibodies against Toxoplasma gondii in human sera. Whereas the reactivity of the developed antigen against IgM antibody was evaluated by western blot and Dot enzyme immunoassay (dot-EIA) analysis.
resultsThe diagnostic performance of the new antigens in IgG ELISA was achieved at the maximum values of 85.43% and 81.25% for diagnostic sensitivity and specificity respectively. The USM.TOXO1 was also proven to be reactive with anti- T. gondii IgM antibody.
conclusionsThis finding makes the USM.TOXO1 antigen an attractive candidate for improving the toxoplasmosis serodiagnosis and demonstrates that multiepitope antigens could be a potential and promising diagnostic marker for the development of high sensitive and accurate assays.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.